Low expression of MCL1-M in patients with MM in anthracycline-based therapy had the same survival with or without bortezomib, suggesting that MCL1-M low MM are more sensitive to anthracyclines and reduce the survival advantage of bortezomib (6). This evidence concerns the gene MCL1 and Miyoshi myopathy.